QWM
CRSP icon

Quadcap Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Quadcap Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
4,747
-93
-2% -$4.9K 0.03% 365
2026
Q1 		$230K Buy
4,840
+980
+25% +$51.7K 0.03% 353
2025
Q4 		$202K Sell
3,860
-3,270
-46% -$196K 0.02% 376
2025
Q3 		$462K Sell
7,130
-240
-3% -$13.8K 0.05% 278
2025
Q2 		$358K Sell
7,370
-243
-3% -$9.4K 0.05% 295
2025
Q1 		$259K Buy
7,613
+205
+3% +$8.69K 0.04% 324
2024
Q4 		$292K Sell
7,408
-60
-0.8% -$2.83K 0.04% 312
2024
Q3 		$351K Buy
7,468
+196
+3% +$9.95K 0.05% 289
2024
Q2 		$393K Sell
7,272
-27
-0.4% -$1.56K 0.07% 277
2024
Q1 		$497K Sell
7,299
-2,087
-22% -$149K 0.11% 211
2023
Q4 		$588K Buy
+9,386
New +$519K 0.15% 179

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadcap Wealth Management's CRSP Position: Q2 2026 in Review

Quadcap Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 1.9% in Q2 2026, selling an estimated $4.9K and leaving 4,747 shares worth $259K. The position accounts for 0.03% of the portfolio, ranked #365.

Quadcap Wealth Management first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $588K in Q4 2023. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Quadcap Wealth Management held 4,747 shares of CRISPR Therapeutics worth $259K as of Q2 2026.
  • Quadcap Wealth Management sold 93 CRISPR Therapeutics shares in Q2 2026, an estimated $4.9K.
  • CRISPR Therapeutics made up 0.03% of Quadcap Wealth Management's portfolio in Q2 2026, its #365 holding.
  • Quadcap Wealth Management first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Quadcap Wealth Management's CRISPR Therapeutics position peaked at $588K in Q4 2023.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Quadcap Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.